Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Third Quarter Trading Statement

27 Oct 2011 07:00

RNS Number : 9104Q
Croda International PLC
27 October 2011
 



27 October 2011

 

Croda International Plc

 

Third Quarter Trading Statement

 

Commenting on trading for the quarter ended 30 September 2011, Martin Flower, Chairman of Croda International Plc, said:

 

"I am pleased to report good turnover and profit progress in the third quarter, driven by sales growth and margin improvement in our core businesses.

 

For the three months ended 30 September 2011, Group sales from continuing operations increased 5.1% to £265.6m (2010: £252.6m). In most business areas we saw an improving trend during the quarter.

 

Operating profit from continuing operations increased 18.3% to £57.6m (2009: £48.7m). Interest costs fell, resulting in continuing pre-tax profit increasing 20.8% to £57.4m (2010: £47.5m).

Year-to-date, the pre-tax profit from continuing operations is up 27.1% at £182.2m (2010: £143.4m).

 

Consumer Care continued to trade strongly in the third quarter, reporting a significant increase in sales (+13.6%) and operating profit (+30.8%) and improved margins versus the corresponding quarter in 2010. Sales and operating profits in all business areas within Consumer Care were well ahead of 2010.

 

Industrial Specialities turnover declined 3.5% against the tough comparatives of a particularly strong third quarter in 2010. The shortfall was in July, with sales in the rest of the period ahead of 2010. Operating profit was down 6.8% with a decrease in commodity and by-product profitability being partially mitigated by stronger performances elsewhere in the sector.

 

Net debt reduced by £15.5m to £237.8m in the quarter (2010: £240.7m) despite completing the £50m buyback programme in the period.

 

Croda continues to trade well and we expect to report further progress in the final quarter and into 2012."

 

For further information please contact:

 

Mike Humphrey

Group Chief Executive

01405 860551

Sean Christie

Group Finance Director

01405 860551

Charlie Armitstead

FTI Consulting

020 7269 7176

 

 

The company will host a conference call for analysts at 8.00am today.

 

Please dial +44 (0)1452 562 815 and quote "Croda International" to gain access to the call.

 

Additional Information

 

 

 

 

 

£m

Q3

9 months

2011

2010

2011

2010

Consumer Care

145.6

128.2

+13.6%

439.2

392.6

+11.9%

Industrial Specialities

120.0

124.4

-3.5%

386.0

371.9

+3.8%

Continuing turnover

265.6

252.6

+5.1%

825.2

764.5

+7.9%

Consumer Care

42.5

32.5

+30.8%

130.5

103.6

+26.0%

Industrial Specialities

15.1

16.2

-6.8%

52.4

45.6

+14.9%

Continuing operating profit

57.6

48.7

+18.3%

182.9

149.2

+22.6%

Operating margin

 

21.6%

 

19.3%

 

 

 

22.2%

 

19.5%

 

 

 

Interest

(0.2)

(1.2)

(0.7)

(5.8)

Continuing pre tax profit

57.4

47.5

+20.8%

182.2

143.4

+27.1%

 

 

 

 

Analysis of Q3 turnover uplift

Price/mix

+18.4%

Volume

-14.8%

Currency translation

+1.5%

Continuing turnover increase

+5.1%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTMFBATMBJTBIB
Date   Source Headline
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech
11th Jan 20233:45 pmRNSDirector/PDMR Shareholding
13th Dec 20223:04 pmRNSDirector/PDMR Shareholding
6th Dec 202212:36 pmRNSDirector/PDMR Shareholding
14th Nov 20223:33 pmRNSHolding(s) in Company
11th Nov 20222:04 pmRNSDirector/PDMR Shareholding
11th Nov 202210:37 amRNSDirector/PDMR Shareholding
11th Nov 202210:33 amRNSDirector/PDMR Shareholding
8th Nov 202211:23 amRNSDirector/PDMR Shareholding
7th Nov 20226:11 pmRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.